Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
Status:
Recruiting
Trial end date:
2027-04-07
Target enrollment:
Participant gender:
Summary
Patients with vulvar cancer who underwent multiple treatments (surgery and radiation therapy
or chemoradiation, radiation therapy or chemoradiation and chemotherapy), or patients not
eligible for standard therapies.
The study aims to:
- Evaluate the oncology response to electroporation after administration of Bleomycin
(BLM) + carboplatinum (CBP )to BLM alone in terms of local progression-free survival
(LPFS) in women with relapsed vulvar cancer after multimodal treatments.
- Compare quality of life (HR-QoL) in the two groups of patients with questionnaires
(FACT-V, FACT-PAL, E5-5L-D5).
- To compare Overall Survival in the two study arms.
- To compare local and systemic toxicity, morbidity and mortality, intraoperative and
post-operative complications among the two study arms.
- To compare costs and cost-effectiveness between the two study arms.
Phase:
Phase 2
Details
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna